Peripheral artery disease in chronic total occlusion percutaneous coronary intervention.

Autor:	Alexandrou M; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Rempakos A; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Mutlu D; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Al Ogaili A; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Carvalho PEP; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Strepkos D; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Choi JW; Texas Health Presbyterian Hospital, Dallas, Texas, USA; Baylor Scott and White Heart and Vascular Hospital, Dallas, Texas, USA., Poommipanit P; University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA., Alaswad K; Henry Ford Cardiovascular Division, Detroit, Michigan, USA., Basir MB; Henry Ford Cardiovascular Division, Detroit, Michigan, USA., Davies R; WellSpan York Hospital, York, Pennsylvania, USA., Jaffer FA; Massachusetts General Hospital, Boston, Massachusetts, USA., Dattilo P; Medical Center of the Rockies, Loveland, CO, USA., Doing AH; Medical Center of the Rockies, Loveland, CO, USA., Azzalini L; Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA., Aygul N; Selcuk University, Konya, Turkey., Chandwaney RH; Oklahoma Heart Institute, Tulsa, Oklahoma, USA., Jefferson BK; Tristar Hospitals, Tennessee, USA., Gorgulu S; Biruni University Medical School, Istanbul, Turkey., Khatri JJ; Cleveland Clinic, Cleveland, Ohio, USA., Young LD; Cleveland Clinic, Cleveland, Ohio, USA., Krestyaninov O; Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia., Khelimskii D; Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia., Frizzell J; St. Vincent Hospital, Indianapolis, Indiana, USA., Goktekin O; Memorial Bahcelievler Hospital, Istanbul, Turkey., Flaherty JD; Northwestern Memorial Hospital, Chicago, Illinois, USA., Schimmel DR; Northwestern Memorial Hospital, Chicago, Illinois, USA., Benzuly KH; Northwestern Memorial Hospital, Chicago, Illinois, USA., Uluganyan M; Benzialem Vakif University, Istanbul, Turkey., Ozdemir R; Benzialem Vakif University, Istanbul, Turkey., Ahmad Y; Yale School of Medicine, Yale University, New Haven, Connecticut, USA., Rangan BV; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Mastrodemos OC; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Burke MN; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Voudris K; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Sandoval Y; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Brilakis ES; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. Email: esbrilakis@gmail.com.
Jazyk:	angličtina
Zdroj:	The Journal of invasive cardiology [J Invasive Cardiol] 2024 Aug 09. Date of Electronic Publication: 2024 Aug 09.
DOI:	10.25270/jic/24.00196
Abstrakt:	Background: The impact of peripheral artery disease (PAD) on the outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is not well studied. Methods: We analyzed the association of PAD with CTO-PCI outcomes using data from the PROGRESS-CTO registry of procedures performed at 47 centers between 2012 and 2023. Results: The prevalence of PAD among 12 961 patients who underwent CTO PCI during the study period was 13.9% (1802). PAD patients were older, more likely to be current smokers, and had higher rates of dyslipidemia, diabetes, cerebrovascular disease, hypertension, prior myocardial infarction, PCI, and coronary artery bypass graft surgery. Their PROGRESS-CTO (1.35 vs 1.22; P < .001) and J-CTO (2.63 vs 2.33; P < .001) scores were higher, lesion length was longer, and angiographic characteristics were more complex. Their access site was more likely to be bifemoral (33.6% vs 30.9%; P = .024) compared with patients with no PAD. Technical (82.9% vs 87.7%; P < .001) and procedural (80.5% vs 86.6%; P < .001) success rates were lower in patients with PAD, while the incidence of major adverse cardiovascular events (MACE) was higher (3.1% vs 1.8%; P < .001), with higher mortality (0.8% vs 0.4%; P = .034), acute myocardial infarction rate (0.9% vs 0.4%; P = .010), and perforations rate (6.6% vs 4.5%; P < .001). In multivariable analysis, PAD was associated with higher MACE (odds ratio [OR]: 1.53; 95% CI, 1.01-2.26; P = .038) and lower technical success (OR: 0.82; 95% CI, 0.69-0.99; P = .039). Conclusions: PAD patients undergoing CTO PCI have higher comorbidity burden, more complex CTOs, higher MACE, and lower technical success.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu